Bank of America Securities analyst Jason Zemansky initiated coverage with a Buy rating on AlloVir (ALVR – Research Report) today and set a price target of $17.00. The company’s shares closed yesterday at $2.47.
According to TipRanks, Zemansky is a 2-star analyst with an average return of 1.0% and a 57.14% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Esperion, Arcus Biosciences, and Insmed.
AlloVir has an analyst consensus of Strong Buy, with a price target consensus of $19.75, a 699.60% upside from current levels. In a report released on August 4, Piper Sandler also maintained a Buy rating on the stock with a $27.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.29 and a one-year low of $2.42. Currently, AlloVir has an average volume of 696.3K.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
